RadNet, Inc. (RDNT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$73.71-1.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · RDNT
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $74 RDNT trades at 2.6× p/s, below its 3.8× p/s peer median, but our blended $14 fair value sits well below the price. We hold it with medium confidence: its earnings are too depressed to value on P/E (we anchor on sales instead). Even valued only for durable growth at sustainable margins, it's worth about $127 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| graham number | 12M | $13.24 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $46.59 | 12.7 | 3.05 | TTM | high |
| Peer P/E | 12M | $14.36 | 18.7 | 0.77 | ntm analyst | high |
| Peer P/S | 12M | $109.45 | 3.8 | 28.82 | TTM | high |
| PEG | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
| $14.89 |
| 33.8 |
| 0.44 |
| TTM |
| high |
| residual income | 12M | $13.57 | — | — | TTM | high |
| triangulated | 12M | $10.54 | 22.9 | 0.46 | Triangulated | high |
| Peer P/E | 3Y | $18.27 | 18.7 | 0.97 | Analyst | medium |
| Peer P/S | 3Y | $147.39 | 3.8 | 38.81 | guidance | medium |
| PEG | 3Y | $32.98 | 33.8 | 0.97 | Analyst | medium |
| Peer P/E | 5Y | $20.36 | 18.7 | 1.09 | Analyst | medium |
| Peer P/S | 5Y | $164.22 | 3.8 | 43.24 | guidance | medium |
| PEG | 5Y | $36.75 | 33.8 | 1.09 | Analyst | medium |